Diflucan

Cerebral Cryptococcosis, Candidemia, Coccidioidomycosis + 22 more

Treatment

24 FDA approvals

20 Active Studies for Diflucan

What is Diflucan

Fluconazole

The Generic name of this drug

Treatment Summary

Fluconazole, commonly known as Diflucan, is a prescription drug used to treat fungal infections in different parts of the body. It was approved by the FDA in 1990 and belongs to a group of anti-fungal medications that includes ketoconazole and itraconazole. Fluconazole is an effective treatment for yeast infections and can be taken orally, with few side effects. In some cases, it can be taken as a single dose to treat a vaginal yeast infection.

Diflucan

is the brand name

image of different drug pills on a surface

Diflucan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Diflucan

Fluconazole

1990

379

Approved as Treatment by the FDA

Fluconazole, also called Diflucan, is approved by the FDA for 24 uses which include Candida pneumonia and Candida (fungus) .

Candida pneumonia

Candida (fungus)

Vaginal Candidiasis

Used to treat Vaginal Candidiasis in combination with Miconazole

Pruritus

Used to treat Pruritus in combination with Miconazole

Candidiasis

Systemic candidiasis

Meningitis, Cryptococcal

Coccidioidomycosis

Oropharyngeal Candidiasis

Candida urinary tract infection

Itching

Used to treat Pruritus in combination with Miconazole

Candidiasis, Vulvovaginal

Used to treat Vaginal Candidiasis in combination with Miconazole

Coccidioidomycosis

Urinary tract infection

Candida (fungus)

Peritonitis

Esophageal Candidiasis

Cerebral Cryptococcosis

Yeast Infection

Bone marrow transplant, cytotoxic chemotherapy

Candidemia

Bone Marrow Transplantation

Candidiasis

prophylaxis of Candida Infections

Effectiveness

How Diflucan Affects Patients

Fluconazole is a medication used to treat fungal infections caused by _Candida albicans_, _Candida glabrata_, _Candida parapsilosis_, and _Cryptococcus neoformans_. It works by blocking the growth of fungus and preventing it from adhering to surfaces, thereby treating the infection and its symptoms. Although it is generally effective, some strains of these organisms may be resistant to fluconazole. It is important to test for susceptibility before using fluconazole. There have been some concerns that fluconazole may interfere with hormones in humans, however

How Diflucan works in the body

Fluconazole works by interfering with the production of a certain type of molecule found in fungi. This molecule, called ergosterol, is important for the fungi cell wall. Fluconazole blocks the enzyme that helps turn lanosterol into ergosterol, meaning the fungi cannot make more of the molecule. This leads to a buildup of lanosterol, which weakens the cell wall and halts the growth of the fungus. Resistance to fluconazole can occur if there is a change in the amount or function of the enzyme, or if access to the enzyme is limited. Other reasons for resistance may also exist.

When to interrupt dosage

The suggested measure of Diflucan is dependent upon the identified condition, such as Candida (fungus), Candida intertrigo and Bone Marrow Transplantation. The magnitude of dosage fluctuates, based on the mode of delivery (e.g. Topical or Powder, for solution) stated in the table below.

Condition

Dosage

Administration

Solid Organ Transplant

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candidiasis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candidiasis, Vulvovaginal

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Urinary tract infection

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Communicable Diseases

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Yeast Infection

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Bone Marrow Transplantation

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Oropharyngeal Candidiasis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Esophageal Candidiasis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candidemia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Coccidioidomycosis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida pneumonia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Pneumonia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida (fungus)

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida intertrigo

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Coccidioidomycosis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

prophylaxis of moderate Pneumocystis pneumonia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Itching

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

prophylaxis of Candida Infections

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida (fungus)

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Warnings

Diflucan Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Fluconazole may interact with Pulse Frequency

There are 20 known major drug interactions with Diflucan.

Common Diflucan Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Fluconazole.

Abrocitinib

Major

The metabolism of Abrocitinib can be decreased when combined with Fluconazole.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Fluconazole.

Acetylsalicylic acid

Major

The metabolism of Acetylsalicylic acid can be decreased when combined with Fluconazole.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Fluconazole.

Diflucan Toxicity & Overdose Risk

The lethal dose of fluconazole in rats is 1271mg/kg. Overdosing on fluconazole can cause hallucinations, confusion, and paranoia. In case of overdose, medical treatment such as gastric lavage and hemodialysis may be needed. People with existing liver problems should use caution when taking fluconazole as it can cause serious liver damage. There are no known risks of using fluconazole during pregnancy, although high doses may cause birth defects. Breastfeeding mothers should also use caution as fluconazole is secreted in breastmilk.

image of a doctor in a lab doing drug, clinical research

Diflucan Novel Uses: Which Conditions Have a Clinical Trial Featuring Diflucan?

37 active trials are underway to assess the efficacy of Diflucan in treating Urinary tract infection, Cerebral Cryptococcosis and Coccidioidomycosis.

Condition

Clinical Trials

Trial Phases

prophylaxis of moderate Pneumocystis pneumonia

0 Actively Recruiting

HIV

155 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Urinary tract infection

0 Actively Recruiting

Candida (fungus)

0 Actively Recruiting

Pneumonia

0 Actively Recruiting

Bone marrow transplant, cytotoxic chemotherapy

0 Actively Recruiting

Candida (fungus)

0 Actively Recruiting

Peritonitis

0 Actively Recruiting

Cerebral Cryptococcosis

1 Actively Recruiting

Phase 2, Phase 3

Candida intertrigo

0 Actively Recruiting

Oropharyngeal Candidiasis

0 Actively Recruiting

Bone Marrow Transplantation

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Candidemia

4 Actively Recruiting

Phase 3, Phase 2

Candida pneumonia

0 Actively Recruiting

Esophageal Candidiasis

0 Actively Recruiting

prophylaxis of Candida Infections

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Candidiasis

0 Actively Recruiting

Diflucan Reviews: What are patients saying about Diflucan?

5

Patient Review

9/6/2016

Diflucan for Yeast Infection of Vagina and Vulva

Diflucan is incredibly effective for me and has completely gotten rid of my yeast infection symptoms within 24 hours. It's also much easier to use than those messy over-the-counter creams. I haven't experienced any side effects, either.

5

Patient Review

8/6/2018

Diflucan for Yeast Infection of Vagina and Vulva

This is the only medication that has helped with my yeast infections. Those over-the-counter ones actually cause irritation and make it worse. I have no side effects from this pill, which is great.

5

Patient Review

3/27/2018

Diflucan for Yeast Infection of Vagina and Vulva

Amoxicillin led to me getting a yeast infection, but this treatment cleared it right up.

4.7

Patient Review

12/15/2016

Diflucan for Yeast Infection of Vagina and Vulva

Diflucan seems to work great, though it gives me a slight headache. I took the first dose and most of my discharge and itching cleared up within a day. Took the second dose five days later as directed, and hoping it will take care of the rest of the discharge. This is my second yeast infection, and I definitely prefer this pill to messy creams. Advil takes care of any headaches.

4.7

Patient Review

7/25/2015

Diflucan for Treatment for Prevention of Vulvovaginal Yeast Infection

I found this medication to be extremely effective, especially in comparison to over-the-counter options. I've never experienced any negative side effects, although I understand that some may occur with prolonged use.

4

Patient Review

2/27/2016

Diflucan for Candida Species Yeast Infection of Abdominal Cavity Lining

This medication cleared up my infection, but unfortunately I'm now dealing with uncomfortable swelling and heartburn.

3.7

Patient Review

4/6/2018

Diflucan for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

I was prescribed this medication for a yeast infection that I got from taking hormone medications. I took 100mg once a day for a week, as directed. However, after finishing the course of medicine, my hair started falling out in clumps. Additionally, my hairline felt sore - like it does when you wear a ponytail for too long. Overall, I don't think I would ever take this medication again.

3

Patient Review

7/6/2022

Diflucan for Thrush

I'm one of the lucky ones who didn't experience any negative side effects. That being said, I don't think this medication did anything to help with my candida.

2.7

Patient Review

10/21/2018

Diflucan for Yeast Infection of Vagina and Vulva

I was put on Augmentin and then got a yeast infection, so the doctor prescribed this. Unfortunately, it's made me really uncomfortable. I had diarrhea for two days straight and major chills last night. I'm still hoping the yeast infection clears up soon.

2.7

Patient Review

9/29/2016

Diflucan for Candida Species Yeast Infection of Abdominal Cavity Lining

Unfortunately, I had a really terrible experience with the side effects of this medication. I wouldn't wish them on anyone.

1.7

Patient Review

10/9/2015

Diflucan for Candidiasis Yeast Infection that Spreads Throughout Body

Took the medication and developed large, unsightly swellings on my lower lip and upper right eyelid. The lip swelling turned black and has left permanent scarring. Not happy with this at all.

1.3

Patient Review

7/31/2018

Diflucan for Yeast Infection of Vagina and Vulva

Day 3 and I'm not seeing any improvement. If anything, it's gotten worse. Augmentin was the original cause of this problem for me; however, I have been eating yogurt twice a day in an effort to improve things.

1

Patient Review

12/20/2021

Diflucan for Skin Infection marked by Ulcers - Cutaneous Leishmaniasis

I had dark marks on my face for months, and this medication did nothing to help them. In fact, I developed blisters on my lips from using it. Needless to say, I won't be using this again.

1

Patient Review

6/28/2022

Diflucan for Presence of Candida Species Yeast in the Blood

I felt incredibly nauseous after taking just one pill, and I also had muscle spasms in my leg during the night. Needless to say, I won't be taking this medication again.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about diflucan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What infections are treated with Diflucan?

"There are many different types of skin infections, marked by different symptoms. Cutaneous leishmaniasis results in ulcers, while ringworm of the scalp causes bald spots. Candida yeast infection of the abdominal cavity lining can cause diarrhea, while ringworm of the hand can cause cracking and peeling of the skin. Ringworm of the groin area can cause intense itching, while athlete's foot causes burning and redness. Ringworm of the body can cause a rash, while tinea versicolor is a fungal infection of the skin that can cause discoloration."

Answered by AI

How long does Diflucan one take to work?

"Fluconazole 150 mg capsules help to treat vaginal yeast infections by killing the Candida yeast. They typically start working within one day, but it may take up to a week for symptoms to completely go away."

Answered by AI

What happens after you take a Diflucan?

"Fluconazole is an antifungal medication that kills the fungus causing the infection. The medicine works by making holes in the cell membrane of the fungus, causing its contents to leak out. This kills the infection and allows the symptoms to improve."

Answered by AI

What is Diflucan prescribed for?

"Fluconazole is used to prevent and treat fungal and yeast infections. It belongs to a class of drugs known as azole antifungals. These drugs work by stopping the growth of certain types of fungus."

Answered by AI

Clinical Trials for Diflucan

Image of Albert Einstein College of Medicine in The Bronx, United States.

Vaginal Estradiol vs Moisturizer for Menopause in Women with HIV

40 - 70
Female
The Bronx, NY

This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.

Phase 4
Waitlist Available

Albert Einstein College of Medicine

Kerry J Murphy, MD

Image of Boise VA Medical Center in Boise, United States.

Pharmacist-Led E-Consults for Lung Health in HIV

18+
All Sexes
Boise, ID

People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs). OPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate. The trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.

Waitlist Available
Has No Placebo

Boise VA Medical Center (+2 Sites)

Kristina A. Crothers, MD

Have you considered Diflucan clinical trials?

We made a collection of clinical trials featuring Diflucan, we think they might fit your search criteria.
Go to Trials
Image of CAN Community Health in Clearwater, United States.

Bictegravir + Emtricitabine + Tenofovir Alafenamide for HIV

18+
All Sexes
Clearwater, FL

Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person's health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, it can be difficult for people who miss doses to get back on treatment right away. There are often several steps and medical appointments required before restarting, such as waiting for lab results or reviewing medical history, which can cause further delays. These additional steps can make it even harder for people to re-engage and may discourage them from returning to care. The REINITIATE study is designed for people living with HIV who have not taken any antiretroviral medications for at least the last 12 weeks. The study will offer participants a way to restart their HIV therapy quickly, by beginning treatment with B/F/TAF on the same day that they return to care. B/F/TAF is a widely used, once-daily HIV regimen, and is recommended in national treatment guidelines. Researchers want to find out if this rapid restart approach is safe and effective, and whether it helps people regain control of HIV and remain in care. The study will also examine how many participants are able to keep the virus at a low level (viral suppression), stay engaged in their HIV care, and tolerate the medication after rapidly restarting treatment. In addition, the study will include interviews with some participants, to gain a better understanding of why they stopped taking their medications and what supported their return to treatment. These insights could help healthcare teams develop better ways to support people living with HIV in the future.

Phase 4
Waitlist Available

CAN Community Health (+9 Sites)

Jessica Altamirano, MD

Gilead Sciences

Image of Coastal Family Health Center in Biloxi, United States.

PEACHES 2.0 Strategies for HIV/AIDS

18+
All Sexes
Biloxi, MS

This project will test ways to reduce stigma in healthcare settings so that more providers offer, and more patients receive, important anal sex-related HIV services, including anorectal sexually transmitted infection (STI) testing, preventive medications, and cancer screening. By evaluating these stigma-reduction strategies in eight clinics in the Mississippi Delta, a region with high rates of HIV and STIs, the research team will learn whether and how these approaches work to improve access to care. The results will help guide healthcare systems in using the most effective methods to reduce stigma, making it easier for people to get prevention services and improving public health.

Waitlist Available
Has No Placebo

Coastal Family Health Center

Bryan Kutner, PhD, MPH

Have you considered Diflucan clinical trials?

We made a collection of clinical trials featuring Diflucan, we think they might fit your search criteria.
Go to Trials
Image of Temple University in Philadelphia, United States.

Mobile Health Application for HIV Prevention and Drug Addiction

18+
Female
Philadelphia, PA

Women involved in the carceral system (WICS) are at higher risk for both HIV and substance use than the general public. WICS are also more likely to engage in behaviors both before and after release that put them at risk for HIV and for overdose, due to opioid use. Despite these risk factors, WICS are less likely to be aware of, use, or adhere to pre-exposure prophylaxis (PrEP) and have less access to medications for opioid use disorder (MOUD). The primary goal of the proposed research is to pilot test a systematically developed PrEP and MOUD uptake intervention for WICS using contextually relevant messages developed through novel formative research methods and embedded in a web-based application in a rigorous research design. The investigators will then test this approach (called PA-LINKS) in a pilot randomized trial with women who have recently been incarcerated in Philadelphia in partnership with Philadelphia FIGHT, a federally qualified health center, for promise of efficacy, and to assess feasibility and acceptability.

Waitlist Available
Has No Placebo

Temple University

Image of Howard Brown Health in Chicago, United States.

Social Network Strategies + Screening for Substance Use Disorder

18+
Male
Chicago, IL

This study aims to improve health care for people who may have HIV or substance use disorders by bringing two services to a large community health center in Chicago. First, the clinic will begin offering routine screening for substance use to all patients. Second, the study will offer a social network-based program that helps people identify friends or partners who may need support and link them to care. The goal is to help more people learn their HIV status, reduce HIV levels in the community, and connect people with substance use treatment when needed. The study will also look at how well these services can be added into everyday clinic practice and what is needed to keep them going over time.

Waitlist Available
Has No Placebo

Howard Brown Health

Britt Skaathun

Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Antibodies for HIV

18 - 55
All Sexes
Birmingham, AL

This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity). The expectation is that ePGT121v1-LS, whether given alone or with PGDM1400LS and VRC07-523LS, by IV or SC, will be safe in generally healthy adults and that the antibodies will not interfere with each other when used together. Approximately 83 volunteers in overall good health and without HIV-1 will be enrolled into two parts (A and B). Part A has six groups. In Groups 1-3, participants will get ePGT121v1-LS given by IV at one of three dose levels: 5 mg/kg, 20 mg/kg, or 40 mg/kg. In Groups 4-6, participants will receive three antibodies-first ePGT121v1-LS, then PGDM1400LS and VRC07-523LS-given by IV at two separate visits that are 24 weeks apart. The total study duration for participants in Part A is 48 weeks of scheduled clinic visits. Part B has two groups. In Group 7, people will get ePGT121v1-LS as SC shots at two visits 12 weeks apart. Each visit will give a total of 375 mg, split into three injections of 125 mg each. In Group 8, people will also have two visits 12 weeks apart and will receive three antibodies as SC shots in this order: first ePGT121v1-LS (125 mg), then PGDM1400LS (100 mg), and then VRC07-523LS (100 mg). The total study duration for participants in Part B is 24 weeks of scheduled clinic visits.

Phase 1
Recruiting

Alabama CRS (Site ID: 31788) (+7 Sites)

Have you considered Diflucan clinical trials?

We made a collection of clinical trials featuring Diflucan, we think they might fit your search criteria.
Go to Trials